CIG-DB: the database for human or mouse immunoglobulin and T cell receptor genes available for cancer studies by Nakamura, Yoji et al.
DATABASE Open Access
CIG-DB: the database for human or mouse
immunoglobulin and T cell receptor genes
available for cancer studies
Yoji Nakamura
1,5, Tomoyoshi Komiyama
2, Motoki Furue
3, Takashi Gojobori
4, Yasuto Akiyama
1*
Abstract
Background: Immunoglobulin (IG or antibody) and the T-cell receptor (TR) are pivotal proteins in the immune
system of higher organisms. In cancer immunotherapy, the immune responses mediated by tumor-epitope-binding
IG or TR play important roles in anticancer effects. Although there are public databases specific for immunological
genes, their contents have not been associated with clinical studies. Therefore, we developed an integrated
database of IG/TR data reported in cancer studies (the Cancer-related Immunological Gene Database [CIG-DB]).
Description: This database is designed as a platform to explore public human and murine IG/TR genes sequenced
in cancer studies. A total of 38,308 annotation entries for IG/TR proteins were collected from GenBank/DDBJ/EMBL
and the Protein Data Bank, and 2,740 non-redundant corresponding MEDLINE references were appended. Next, we
filtered the MEDLINE texts by MeSH terms, titles, and abstracts containing keywords related to cancer. After we
performed a manual check, we classified the protein entries into two groups: 611 on cancer therapy (Group I) and
1,470 on hematological tumors (Group II). Thus, a total of 2,081 cancer-related IG and TR entries were tabularized.
To effectively classify future entries, we developed a computational method based on text mining and canonical
discriminant analysis by parsing MeSH/title/abstract words. We performed a leave-one-out cross validation for the
method, which showed high accuracy rates: 94.6% for IG references and 94.7% for TR references. We also collected
920 epitope sequences bound with IG/TR. The CIG-DB is equipped with search engines for amino acid sequences
and MEDLINE references, sequence analysis tools, and a 3D viewer. This database is accessible without charge or
registration at http://www.scchr-cigdb.jp/, and the search results are freely downloadable.
Conclusions: The CIG-DB serves as a bridge between immunological gene data and cancer studies, presenting
annotation on IG, TR, and their epitopes. This database contains IG and TR data classified into two cancer-related
groups and is able to automatically classify accumulating entries into these groups. The entries in Group I are
particularly crucial for cancer immunotherapy, providing supportive information for genetic engineering of novel
antibody medicines, tumor-specific TR, and peptide vaccines.
Background
The immune system is inherent in vertebrates and pro-
vides protection against toxic substances or infectious
diseases. Two antigen receptor proteins, immunoglobu-
lin (IG) expressed on B lymphocytes or secreted by
plasma cells, and the T-cell receptor (TR), expressed on
T lymphocytes, are key molecules for humoral immunity
and cell-mediated immunity, respectively [1]. Each of
these proteins consists of two chain types, called light
and heavy chains for IG (there are two identical light
chains and two identical heavy chains in an IG), and
alpha and beta chains, or gamma and delta chains for
TR. Each chain contains, at its N-terminal end, a vari-
able (V) domain which participates in antigen recogni-
tion. The V domain is encoded by two or three genes, a
V gene, a diversity (D) gene (for heavy, beta and delta
chains) and a joining (J) gene, which rearrange through
somatic recombination [2]. In the V domain, three com-
plementarity determining regions (CDRs), which are
especially sequence-diversified, contact antigenic epi-
topes. In particular, the third CDR (CDR3) is the most
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recombination and is considered crucial for the recogni-
tion of epitopes [3-5].
Cancer cells proliferate abnormally compared to nor-
mal cells, often expressing proteins (tumor-associated
antigens) that cannot be seen in normal developmental
stages [6]. In cancer studies, monitoring the immune
status of patients is thus very important for diagnosis, as
expression of an autoantibody [7] and the activation of
cytotoxic T lymphocytes (CTLs) [8] specific to tumor-
associated antigens are observed. In hematological
tumors, such as leukemia or lymphoma, IG and TR
themselves are the subject of investigation, because the
encoding genes are often mutated by translocation in
tumor B or T cells [9]. Moreover, in recent years, these
antigen receptor proteins have attracted attention in the
field of cancer immunotherapy to elevate the patient’s
immune response against tumor cells with few side-
effects [10,11]. In cellular immunotherapy, T cells recog-
nizing tumor-associated antigens can be administrated
back to patients after ex vivo culture and processing for
immune response enhancement.
During the last decade, monoclonal antibodies have
been sought and engineered as candidates for molecular
target drugs [12]. These molecules can recognize the
cancer cells expressing tumor-associated antigens with
high affinity and selectivity, triggering anticancer effects
[12,13], such as complement dependent cytotoxicity,
antibody-dependent cellular cytotoxicity, inhibition of
angiogenesis, and induction of apoptosis. In general, the
source of antibody medicines is the human or mouse: (i)
fully murine, (ii) chimeric with V domains from the
mouse and constant regions from the human, and (iii)
humanized or human antibodies have been developed
[12]. For instance, trastuzumab (trade name Herceptin),
a humanized antibody that targets the human epidermal
growth factor receptor type 2 protein, has shown suc-
cess in the treatment of breast cancer [14]. Around 10
antibody medicines in cancer therapy are now approved
and another 30 are being assessed in clinical trials in the
USA [12].
Cancer vaccines are another type of immunotherapy,
in which partial epitope peptides of tumor-associated
antigens are administered to patients to potentiate CTL
activity [15]. TR on CD8+ T cells recognize the peptide
vaccines bound with human leukocyte antigens (HLA),
which are displayed by antigen-presenting cells, and
enhance cytotoxic activity against cancer cells carrying
the peptides [16]. Each peptide vaccine is, in general, 9-
10 amino acids long and selected according to the
patient’s HLA allele type.
These immunotherapeutic studies have emphasized
the importance of genetic engineering of IG and TR
proteins and peptide vaccines at the sequence level
[17-21]. Currently, there are several immunological gene
databases available online, such as IMGT®, the inter-
national ImMunoGeneTics information system® [22] and
the Immune Epitope Database and Analysis Resource
(IEDB) [23]. Although the contents of these databases
are well-annotated and specific to genetic information
on IG, TR, and their epitopes, there are still gaps
between this information and the clinical application in
cancer research. In particular, the information supplied
is too broad for clinicians and pharmacologists (for
example, such databases store the data from a large vari-
ety of organisms and the majority are unrelated to can-
cer) to easily obtain the information required for
patient-specific treatment. To address these issues, we
have developed a freely accessible database, the Cancer-
related Immunological Gene Database (CIG-DB). The
database integrates the information on IG, TR, and epi-
topes reported in cancer studies, and presents sequence
analysis tools, and structural data.
Construction and content
Data integration
The CIG-DB is a semi-automated database consisting of
four tables, two of which are for IG and TR proteins,
respectively. All the included proteins are only derived
from the human or mouse. The other two tables are for
epitopes of IG or TR, where we collected the amino
acid sequences from a variety of organisms regardless of
whether they were cancer-related or not. Since the avail-
able amount of cancer-related epitope data is still small,
a large number of sequences are considered useful for
further comparative analysis.
First, to thoroughly check all public IG/TR proteins of
human and mouse origins, we downloaded their annota-
tion data from GenBank/DDBJ/EMBL by keyword
search. Then, the Geninfo Identifier (GI) and accession
numbers, full amino acid sequences, and references
were extracted and tabularized as a local proto-database.
CDR3 sequences were also extracted from the full
sequences using a pattern-matching program to find the
N- and C-terminal borders. The program detects con-
served motifs flanking the CDR3 region using regular
expressions, such as the second cysteine and its adjacent
residues as the N-flanking sequence and a WGXG motif
as the C-flanking sequence. The V and J gene reper-
toires were assigned according to IMGT® nomenclature
[24,25] and BLAST [26] matching. Furthermore, we
obtained structural data of the IG/TR proteins from the
Protein Data Bank (PDB) [27], if any, and the informa-
tion was merged with the GenBank annotation. We thus
obtained a total of 32,240 entries for IG and 6,068 for
TR, as of October 1, 2009 (Table 1). Next, for each of
the entries, we obtained the corresponding 2,740 MED-
LINE reference data from PubMed at the National
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number of references is approximately one order of
magnitude smaller than that of the receptor sequences,
because multiple IG or TR sequences are often reported
in a single reference. We then selected 578 MEDLINE
reference texts in which cancer-related keywords ("mela-
noma,”“ carcinoma,”“ sarcoma,” etc.) are contained in at
least one of either the MeSH terms, title, or abstract
sentences. When we annotated the IG/TR entries
according to the selected references, we noticed that the
IG/TR entries screened were used for the following
cases in cancer studies: (i) studied in the context of can-
cer therapy (specific TR and antibodies monitored after
administration of peptide vaccines in immunotherapy,
monoclonal antibodies specific to cancer markers, etc.)
and (ii) isolated from hematological tumors such as
leukemia, lymphoma, and myeloma (survey of mutation
in IG or TR gene locus, etc.). Therefore, we manually
classified the IG/TR entries into these two groups,
named Groups I (cancer therapy) and II (hematological
tumors), and the corresponding entries were tabularized
in the same format as the above-mentioned proto-data-
base. Finally, we obtained a total of 2,081 cancer-related
receptor entries, 1,605 for IG and 476 for TR (Table 1).
Regarding epitopes, the interaction between IG/TR
and an epitope is the specific focus of this database. The
source of epitope sequences was public databases: the
IEDB, Bcipep [28], and the HIV sequence database [29],
and where possible the PDB, if epitopes were crystallized
as bound with IG or TR. We then extracted the protein
or peptide epitopes and selected those whose antigen
receptor sequences are known. The matching criteria
were as follows: (i) the complex structure of the antigen
receptor and epitope are already in the PDB, (ii) for the
epitopes from the IEDB, the GI numbers of the recep-
tors are found in the IG/TR tables of the CIG-DB, and
(iii) manual check of references. As a whole, we
obtained a total of 920 epitope sequences, 772 for IG,
and 148 for TR (Table 1). Antigen-presenting cells dis-
play as T cell epitopes around 9-mer peptides, and TR
epitopes are therefore always of linear sequences. In the
case of IG epitopes, conformational ones neighbored
through antigen folding are possible. To show the key
residues involved in the interaction with the antigen
receptor, residues were highlighted based on the dis-
tances of the residues to the receptor’sC D R 3( <4
angstroms).
Reference clustering and classification
In the current version of the CIG-DB, as mentioned
above, we manually checked the references to classify
the IG and TR entries into two cancer-related groups.
We further prepared an automated classification
method based on text mining, training, and clustering
algorithms. For training, we appended one additional
group (Group III) of unrelated references (Table 2),
which was wrongly selected by cancer-related keywords
and dropped by manual classification. First, we parsed
each of the MEDLINE text format data of the three
groups using the tm library of the R program and com-
puted a term frequency vector for the words occurring
in the MeSH terms, title, and abstract, after processing
and stemming. Figure 1 shows the result of principal
component analysis (PCA), which plots the first and
second principal components (PC1 and PC2) using all
the term frequency vectors, suggesting that the three
groups are distributed separately from each other for
both IG and TR references. Next, we averaged and
merged all the frequency vectors of the references in
each group and calculated a canonical discriminant
function, using the Mahalanobis distance between any
Table 1 CIG-DB statistics as of 1 October 2009
Data content IG TR Total
Screened from NCBI and PDB 32240 6068 38308
Cancer-related 1605 476 2081
Human 879 318 1197
Mouse 726 158 884
Group I
a 397 214 611
Group II
b 1208 262 1470
Chains
Light 791
Heavy 814
Alpha 185
Beta 288
Gamma
c 3
Epitope sqeuences 772 148 920
aThis group is involved in cancer therapy such as antibody medicines.
bThis group is involved in expression in hematological tumors.
cA minor TCR allele.
Table 2 Classification of cancer-related references in
CIG-DB
Data content IG TR Total
Collected from PubMed 2054 686 2740
Screened by keywords 446 132 578
Manually classified
a
Group I 120 34
Group II 139 37
(Group III) 187 61
aGroups I and II are the same as in Table 1. Group III is a group of wrongly
screened references.
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shown below:
dx x x ij i j
T
ij j
(, ) ( ) ( )   =− −
− ∑
1
Here, d(xi, μj) is the distance between a term fre-
quency vector (xi) of reference i and the mean vector
(μj) of group j (j = 1,2,3), Σj
-1 is an inverse matrix of the
variance-covariance matrix of group j,a n dT indicates
the transposition of the vector. In the discriminant func-
tion, each reference was classified into the group in
which d became a minimum value. To validate the dis-
criminant function, we performed a leave-one-out cross
validation (Table 3). The accuracy rates of classification
were very high: 94.6% for IG and 94.7% for TR.
Utility
Reference and sequence search
The CIG-DB provides two search engines: (i) sequence
search and (ii) reference search, which users can select
on the home page.
Sequence search
Users can perform keyword searches by GI numbers,
amino acid sequences, or GenBank accessions of IG/TR/
epitope entries. Users can select eight search conditions,
“Contains/Does not contain,”“ Equals/Does not equal,”
“Starts with/Does not start with,” and “Ends with/Does
not end with.” The search result is shown as a table that
can be sorted in ascending or descending order. Most
importantly, the sequence search for IG or TR entries
can be focused on cancer-related sequences by checking
the filter option box. In a resultant table, GI numbers
and references are linked to GenBank and PubMed
online, respectively, and the reference IDs (i.e., PubMed
IDs) shown are numbered as “1” (cancer therapy) or “2”
(hematological tumors). The same search engine is also
available for epitope entries.
Reference search
Users also can search for IG/TR entries by MeSH terms,
words in the title or abstract, names of authors, journals,
or publication dates, and thus narrow down research
fields of interest. This feature is an advantage of the
CIG-DB, because such a detailed reference search is not
offered by other public immunological databases. Figure
2a shows an example of a search result using the name
of an antibody medicine against breast cancer, “Hercep-
tin.” The reference search result can be reflected to the
subsequent sequence search to corresponding IG/TR/
epitope entries by a check box, so that users can see
Figure 1 The result of principal component analysis on cancer-
related immunoglobulin (IG) and T-cell receptor (TR)
references. PC1 and PC2 indicate scores of the first and second
principal components, respectively. (a) IG references and (b) TR
references.
Table 3 Validation of reference classification by canonical
discriminant analysis
Predicted groups
Protein and
group
a
Group I Group II Group III Total Accuracy (%)
IG Group I 111 0 9 120 92.5
Group II 0 128 11 139 92.1
Group III 0 4 183 187 97.9
Total 422/446 94.6
TR Group I 31 0 3 34 91.2
Group II 0 33 4 37 89.2
Group III 0 0 61 61 100.0
Total 125/132 94.7
aGroups I, II and III are the same as in Tables 1 and 2.
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reference (Figure 2b).
Sequence analysis tools
In clinical study, one may determine the sequences of
IG or TR specific to tumor-associated antigens from a
patient’s B or T cells and compare these with public
sequences. The CIG-DB thus provides BLAST (Ver.
2.2) and CLUSTALW [30] (Ver. 1.83) tools for
sequence similarity search and alignment (Figure 3).
Here users can compare the in-house sequences with
cancer-related sequences in the CIG-DB, or with all
public IG/TR sequences regardless of cancer studies in
the proto-database. It is also possible to perform the
Figure 2 A search interface of the Cancer-related Immunological Gene Database (CIG-DB). (a) An example of search results where the
word “Herceptin” is queried against references in the CIG-DB. (b) The subsequent sequence search result from (a). A check box for reflecting the
reference search result to sequence search is indicated by a red arrow.
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For example, after a reference or sequence search, the
result can be subsequently utilized for such compara-
tive analyses. The matched sequence list by BLAST
and multiple alignment by CLUSTALW are download-
able in text format.
3D structure visualization and modeling
For the entries merged from the PDB, which are either
for a receptor alone or a receptor-epitope complex, the
tertiary structures are visualized by a JAVA applet based
on Jmol [31] (Figure 4). This viewer can be customized
so that interacting residues are highlighted. Particularly,
Figure 3 Sequence analysis tools of CIG-DB. (a) An example of BLAST query and result pages. (b) An example of CLUSTALW query and result
pages. Both analyses were performed from the search result page in Figure 2b.
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PDB is viewed as bound with the antigen receptor, and
the applet allows users to investigate the interaction
between CDR3 and epitope residues (atomic distance,
etc.). In addition, the CIG-DB offers predicted structures
for non-PDB IG/TR entries using MODELLER [32], a
protein 3D modeling software based on the homology
modeling method. In MODELLER, an amino acid
sequence is compared against a 1D sequence database
consisting of known PDB structures. PDB structures
whose sequences are similar to that of the query are
used as templates in 3D alignment, followed by energy
optimization of aligned structures. In the CIG-DB, the
templates are local data of human and mouse IG/TR
proteins collected from the PDB, whose backbone struc-
tures are sufficiently conserved. For each of the non-
PDB IG/TR entries, five predicted structures and their
scores (objective functions) in optimization are calcu-
lated, and users can download these models in PDB for-
mat for further refinement by structure calculation (e.g.,
molecular dynamics or docking simulation).
Database implementation and update
The CIG-DB is a Java web application developed using
an open source Ajax framework, ZK, which uses
MySQL as a database backend. As a high performance
search engine, this database is equipped with Apache
Lucene. The application runs on a servlet container,
Apache Tomcat. An update of the basic contents is
semi-automatic, achieved by Perl and Shell scripts.
In the future, the reference classification script by R
programs will be integrated into the automation.
Discussion
Immunotherapy is now an effective treatment for can-
cer, where the information on cancer-antigen-specific
IG or TR as well as the epitopes, is essential for its use.
In particular, genetic engineering, such as the improve-
ment of antibody sequences as molecular target drugs
or the design of epitope peptides for cancer vaccines,
are of great interest to clinicians and pharmacologists.
For such studies, a sequence-based database for cancer
immunological genes has potential utility. In addition,
sequence comparison tools and structural data are use-
ful for genetic engineering, combined with library
screening methods in a laboratory [33,34]. Our database,
the CIG-DB, thus may meet the needs of researchers
involved in such cancer studies. Moreover, this database
is also designed as a reference-based platform, equipped
with a search engine by MeSH terms, title, and abstract
words (Figure 2a). In previous public databases, one
could find the immunological gene sequences, but the
references were not always related to cancer, or one
could search for cancer-related papers, but the
sequences frequently were undetermined. Our database
avoids such inconveniences and users can easily obtain
the cancer-related IG/TR sequences that are available.
For comparison, IMGT also provides with the data
sheets on therapeutic monoclonal antibodies related to
oncology http://www.imgt.org/mAb-DB/query, but does
not yet encompass the information about cancer vac-
cines and TRs specific to tumor-associated antigens.
The IEDB is an exhaustive epitope resource and covers
a wide range of experimental details, but the search
option is not optimized to find cancer-related protein/
peptide sequences.
Considering their application in cancer studies, IG and
TR proteins are derived from two mammals, the human
and the mouse. In this study, it was found that such
cancer-related IG/TR proteins can be classified into two
groups, namely, cancer therapy (Group I) and hematolo-
gical tumors (Group II). One more group (Group III) of
unrelated references includes papers mainly involving
experiments about hybridoma using “myeloma” or those
about irrelevant “tumors,” which are therefore wrongly
selected by keyword matching. The classification of can-
cer-related IG and TR is thus very important for ensur-
ing a high quality of the CIG-DB. Maintenance of the
current version of the CIG-DB is semi-automated from
initially obtaining the sequence data to presenting the
final tables on the graphical user interface. Manual
operation is only necessary for the very classification of
IG and TR annotation entries into the two groups by
Figure 4 A3 Dv i e w e ro fC I G - D B . The entries containing two
words, “cancer” and “testis,” were searched against the column of
“Epitope name” in TR-epitope table (EPI TCR table). A 3D structure
of the top hit (PDB code = 2F53, the complex between the T-cell
receptor and cancer/testis antigen 1B peptide) is shown. The
epitope molecule is highlighted in green by checking a box in the
viewer.
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troublesome task for future updates. To reduce this bur-
den, we prepared a computational classification program
inside the database. As a basis for this step, PCA results
suggest that the two groups can be discriminated from
each other by the term frequencies in MEDLINE texts
(Figure 1). Although Group III overlaps somewhat with
Group II in the case of IG references, the distributions
can be statistically discriminated from each other (P <
0.001, multivariate analysis of variance). In this study,
we calculated a canonical discriminant function using a
set of references that were classified manually in the
current version of the database as a training dataset. We
evaluated the function by leave-one-out cross validation
and obtained high accuracy rates (Table 3), strongly sug-
gesting that our method can be applicable for an auto-
mated update. For the next update, this procedure may
possibly be integrated into the maintenance programs of
the CIG-DB. Alternatively, we will perform a manual
classification and calculate the discriminant function
again over a few more updates, further improving the
accuracy of the database.
This database provides structural data of antigen
receptors. Particularly, for all non-PDB IG/TR entries,
the five predicted structural models are available in PDB
format, which allows users to study the interaction
between IG/TR and the epitope using molecular
dynamics or docking simulation. This is an advantage of
our database over other public databases, such as IMGT
and the IEDB which provide only known structures. It
s h o u l db en o t e dt h a tt h ec o mbinatorial study using
these tools and IG/TR data in Group I are efficient for
cancer immunotherapy, in which genetic design and
engineering are performed for developing novel antibody
medicines, tumor-specific TR, and peptide vaccines with
potent anticancer effects. Recently, new technologies
have allowed rapid cloning of effective antibodies to spe-
cific antigens [35,36]. It is thus likely that a large num-
ber of antibodies and TR for tumor-associate antigens
will be open for genetic improvement in the near future.
Since the CIG-DB is a semi-automated database, the lat-
est information will be quickly reflected there. We
believe that accumulation of IG/TR/epitope data will
enhance the usefulness of this database in clinical cancer
studies.
Conclusions
The CIG-DB is designed to serve as a bridge between
immunological gene data and cancer studies, presenting
annotations of IG, TR, and their epitopes. In its current
version, the database has 2,081 cancer-related human
and murine receptor entries (1,605 for IG and 476 for
TR), and 920 entries for epitopes bound with receptors
from a variety of organisms. Regarding IG and TR
proteins, this database further provides a helpful guide
to two detailed groups; one for cancer therapy and the
other for hematological tumors. For the next update, we
have developed a powerful method to automatically
classify cancer-related entries into these two groups.
The high precision (~95% accuracy) shown in validation
assessments is promising for the efficient performance
of the database. Moreover, the CIG-DB is equipped with
sequence- and reference-search engines and analysis
tools, the results of which can be utilized for advanced
studies. In particular, the database will play important
roles in cancer immunotherapy, by integrating the accu-
mulating patient-specific IG/TR/epitope sequence data
by novel cloning technologies.
Availability and requirements
The CIG-DB is available without charge or registration
at http://www.scchr-cigdb.jp/. We have confirmed that
the web site can be viewed by Internet Explorer 7 or
later, Safari 3, and Firefox 3. The Java Runtime Environ-
ment (JRE 1.5 or higher) is required for displaying
3D structures by Jmol applet.
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